SCHEMBL8209103

SCHEMBL8209103

CC(C)NC(=O)c1cccc(C(=O)NCc2cnn(-c3ccc(F)c(Cl)c3)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.44
CNR2 P34972 2/20 0.41
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALK Q9UM73 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CNR1 P21554 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CTSA P10619 1/20 0.38
NTRK1 P04629 3/20 0.38
KLKB1 P03952 1/20 0.38
KLK1 P06870 1/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 1/20 0.38
P2RX7 Q99572 1/20 0.37
DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8210993 0.90 ADRB2 (0.46) ADRB2CNR2KDM4EALDH1A1POLB
SCHEMBL17011993 0.89 ADRB2 (0.44) ADRB2KDM4EALDH1A1SUCNR1POLB
SCHEMBL12853294 0.89 KDM4E (0.44) ADRB2KDM4EALDH1A1POLBNPSR1
SCHEMBL8210996 0.89 DHODH (0.44) ADRB2KDM4ECYP1A2CYP2C19NPSR1
SCHEMBL12853310 0.88 SUCNR1 (0.51) ADRB2CNR2KDM4EALDH1A1SUCNR1
SCHEMBL8211521 0.87 ADRB2 (0.57) ADRB2CNR2KDM4EALDH1A1POLB
SCHEMBL8205838 0.85 ADRB2 (0.38) ADRB2KDM4EALDH1A1POLBNTRK1
SCHEMBL17011995 0.84 ADRB2 (0.46) ADRB2KDM4EALDH1A1POLBNPSR1
SCHEMBL8209034 0.84 ADRB2 (0.47) ADRB2KDM4ECYP1A2CYP2D6CYP2C19
SCHEMBL8205629 0.84 CNR1 (0.43) ADRB2CYP1A2ALDH1A1CNR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 ADRB2 3238/4885CNR2 1846/4885KDM4E 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.